Glomerular Cell-Cell Crosstalk and Injury
Glomerular Cell-Cell Crosstalk and Injury
批准号:
8506338
负责人:
Erwin P. Bottinger
金额:
$36.87万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-15 至 2018-02-28
关键词:
AffectAlbuminsAlbuminuriaAmericanAnimal ModelApoptosisBiopsyCell Culture TechniquesCell LineCellsCharacteristicsChronic Kidney FailureCoculture TechniquesConditioned Culture MediaCreatinineDevelopmentDicer EnzymeDiseaseDisease ProgressionDoxycyclineEndothelial CellsEndothelin-1Focal Segmental GlomerulosclerosisFoot ProcessFunctional disorderHealth ExpendituresHomeostasisHumanIn VitroInjuryKidneyKnock-outLeadLesionLigandsMediatingMicroRNAsMitochondriaModelingMolecularMorphologyMusOxidative StressPhenotypePhosphotransferasesProcessPublic HealthRecoveryRenal glomerular diseaseResearchSclerosisSignal TransductionSmall Interfering RNAStress Response SignalingSuperoxidesSystemTimeTransgenic MiceUp-RegulationUrineWT1 geneWithdrawalWorkbaseburden of illnesscell injurycell typeglomerulosclerosisin vivoinhibitor/antagonistmitochondrial dysfunctionmouse modelmutantnovelpodocytepreventpublic health relevancereceptorresearch studyresponsetherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Segmental sclerosis is a characteristic lesion defining both primary and secondary glomerulosclerosis. In most diseases causing glomerulosclerosis, Tgfb expression in podocytes is a stress response signal associated with sclerosis lesions. To define precisely how activation of Tgfb type I receptor (TbrI) signaling in podocytes affects glomerular cells in vivo, we generated a transgenic mouse model (PodTbrI(AAD) that enables conditional (Doxycycline-inducible) expression of a constitutively-active TbrI mutant (TbrI(AAD). When TbrI(AAD) signaling is activated in podocytes, mice eventually develop albuminuria and subsequently progressive glomerulosclerosis associated with podocyte depletion. However, podocyte morphology remains normal while podocytes initially release endothelin 1 (Edn1) to cause endothelial cell mitochondrial oxidative stress (ENDO mtStress) and endothelial dysfunction (ED). Furthermore, treatment with an inhibitor of endothelin 1 type A receptor (Ednra) or mitochondrial-targeted superoxide scavenger, eliminated ENDO mtStress and prevented albuminuria and segmental sclerosis. These results suggest a novel podocyte-to-endothelial-to- podocyte crosstalk, where Edn1/Ednra meditated ENDO mtStress and ED is essential for manifestation of podocyte damage/loss in progressive sclerosis. Using in vitro co-culture system of PodTbrI(AAD) podocytes and mouse glomerular endothelial cells (mGECs), we confirmed that Dox-activated PodTbrI(AAD) conditioned medium or Edn1 treatment of mGEC was sufficient to initiate ED, and subsequent mGEC supernatant was sufficient to induce podocyte apoptosis. Finally, we timed Dox withdrawal and found that 100-fold increase of urine albumin/creatinine ratio and at least 40% loss of podocytes were phenotypic markers for irreversible progression of sclerosis even in the absence of Dox. HYPOTHESIS: Perturbation of podocyte homeostasis can be associated with Edn1 release to initiate Edn1/Ednra-mediated mtStress and dysfunction of adjacent endothelial cells, which in response release soluble signal(s) that mediate progressive damage and depletion of adjacent podocytes characteristic of progressive segmental sclerosis. SPECIFIC AIMS: 1) Identify soluble molecular signal(s) produced by endothelial cells, subject to Edn1-activated dysfunction, that is required for manifestation of podocyte apoptosis in vitro. 2) Refine and pinpoint the phenotypic markers (thresholds) and the underlying molecular mechanisms that demarcate precisely the onset of irreversible progression of glomerulosclerosis in PodTbrI(AAD) mice. 3) Delineate whether segmental sclerosis and podocyte lesions in human primary and secondary podocytopathies are correlated with underlying podocyte-endothelial crosstalk in human kidney biopsy cases. LONGTERM: the proposed studies should elucidate the requirements and mechanisms for interdependent signaling crosstalk between dysregulated podocytes and endocapillary cells that determine irreversible segmental sclerosis characteristic of glomerular disease progression. This research aims to identify novel glomerular lesion-specific therapeutic targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary Care
-
批准号:8682897
-
项目类别:
-
资助金额:$96.89万
-
财政年份:2013
-
负责人:Erwin P. Bottinger
-
依托单位:
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary Care
-
批准号:8514374
-
项目类别:
-
资助金额:$73.96万
-
财政年份:2013
-
负责人:Erwin P. Bottinger
-
依托单位:
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary Care
-
批准号:9145325
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2013
-
负责人:Erwin P. Bottinger
-
依托单位:
Biorepository for Genomic Medicine in diverse Communities
-
批准号:8509278
-
项目类别:
-
资助金额:$27.12万
-
财政年份:2011
-
负责人:Erwin P. Bottinger
-
依托单位:
Biorepository for Genomic Medicine in diverse Communities
-
批准号:9115828
-
项目类别:
-
资助金额:$8.95万
-
财政年份:2011
-
负责人:Erwin P. Bottinger
-
依托单位:
Biorepository for Genomic Medicine in diverse Communities
-
批准号:8193636
-
项目类别:
-
资助金额:$84.75万
-
财政年份:2011
-
负责人:Erwin P. Bottinger
-
依托单位:
Biorepository for Genomic Medicine in diverse Communities
-
批准号:8729076
-
项目类别:
-
资助金额:$18.05万
-
财政年份:2011
-
负责人:Erwin P. Bottinger
-
依托单位:
Biorepository for Genomic Medicine in diverse Communities
-
批准号:8537968
-
项目类别:
-
资助金额:$104.26万
-
财政年份:2011
-
负责人:Erwin P. Bottinger
-
依托单位:
Biorepository for Genomic Medicine in diverse Communities
-
批准号:8319368
-
项目类别:
-
资助金额:$82.54万
-
财政年份:2011
-
负责人:Erwin P. Bottinger
-
依托单位:
Genetic Programming in Progressive Renal Disease
-
批准号:8010742
-
项目类别:
-
资助金额:$10.68万
-
财政年份:2010
-
负责人:Erwin P. Bottinger
-
依托单位:
The New York CKD Biomarker Discovery Program
-
批准号:7800090
-
项目类别:
-
资助金额:$60.58万
-
财政年份:2009
-
负责人:Erwin P. Bottinger
-
依托单位:
The New York CKD Biomarker Discovery Program
-
批准号:8312652
-
项目类别:
-
资助金额:$58.88万
-
财政年份:2009
-
负责人:Erwin P. Bottinger
-
依托单位:
The New York CKD Biomarker Discovery Program
-
批准号:7938633
-
项目类别:
-
资助金额:$58.88万
-
财政年份:2009
-
负责人:Erwin P. Bottinger
-
依托单位:
The New York CKD Biomarker Discovery Program
-
批准号:8537432
-
项目类别:
-
资助金额:$58.73万
-
财政年份:2009
-
负责人:Erwin P. Bottinger
-
依托单位:
Role and Mechanisms of Epithelial Injury in Diabetic Nephropathy
-
批准号:7896030
-
项目类别:
-
资助金额:$10.37万
-
财政年份:2009
-
负责人:Erwin P. Bottinger
-
依托单位:
The New York CKD Biomarker Discovery Program
-
批准号:8113928
-
项目类别:
-
资助金额:$58.88万
-
财政年份:2009
-
负责人:Erwin P. Bottinger
-
依托单位:
Towards Molecular Diagnostics of Glomerular Disease
-
批准号:7578177
-
项目类别:
-
资助金额:$30.35万
-
财政年份:2006
-
负责人:Erwin P. Bottinger
-
依托单位:
Towards Molecular Diagnostics of Glomerular Disease
-
批准号:7217515
-
项目类别:
-
资助金额:$30.97万
-
财政年份:2006
-
负责人:Erwin P. Bottinger
-
依托单位:
Towards Molecular Diagnostics of Glomerular Disease
-
批准号:7028518
-
项目类别:
-
资助金额:$33.32万
-
财政年份:2006
-
负责人:Erwin P. Bottinger
-
依托单位:
Towards Molecular Diagnostics of Glomerular Disease
-
批准号:7379955
-
项目类别:
-
资助金额:$30.35万
-
财政年份:2006
-
负责人:Erwin P. Bottinger
-
依托单位:
海外基金